retatrutide news recency 3 New Phase data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide Phase 3: 60% Achieved

Safety Considerations and UK Regulatory Status Retatrutide is not MHRA-approved, meaning self-use outside clinical trials carries risks including product impurity, incorrect dosing, gastrointestinal adverse effects, and no pharmacovigilance oversight

Reddys face manufacturing complexities (Times of India, 2025)

Interestingly, in echidna GLP-1 there is less conservation of the receptor binding residues with additional changes at the N-terminal receptor binding Phe 12 (conservatively substituted to Tyr) and Asp 15 (changed to Glu) residues

FGFR4/1, fibroblast growth factor receptor4/1

tirzepatide and retatrutide engineer single molecules to hit two and three incretin/glucagon receptors respectively

Mounjaro and Wegovy vs